MRK · News · 20261106N

Litigation and Legal Risk

Merck & Co., Inc. · 2026-11-06 · Importance 41 · Surprise 48

Halozyme’s third-quarter 2026 earnings call highlighted a patent dispute with Merck, and a separate report described the Merck litigation as ongoing. Halozyme reported SG&A expense of $58.2 million, up from $46.1 million a year earlier, partly attributing the increase to higher consulting fees including Merck litigation costs. The reports did not specify the claims, jurisdiction, potential liability, or the amount of litigation-related costs.

Key facts

• Halozyme's third-quarter 2026 results coverage described its litigation with Merck as ongoing. source
• A patent dispute between Halozyme and Merck was a focus of investor attention during Halozyme's third-quarter earnings call. source